Kathryn King
FDA/CDER/ Office of Biotechnology Products
Kathryn King earned her Ph.D. from the Department of Biochemistry and Molecular Biology at the Victoria University of Manchester in the UK. Following a post-doc in the Department of Medicine at Cambridge University in the UK, she moved to the US FDA in 2000. At the FDA she is employed as a Staff Scientist/Product Quality Reviewer in the Office of Biotechnology Products, Division of Biotechnology Products Research and Review 1, where she serves as a product quality (CMC) reviewer for recombinant therapeutic protein products and carries out mission relevant research on epithelial cancers. She is currently serving as the FDA/CDER topic lead on the ICHQ5A(R2) Expert Working group.